Published in J Clin Invest on February 01, 2008
Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med (2009) 2.51
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. Nat Med (2014) 2.30
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A (2009) 1.80
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Nanoscale X-ray microscopic imaging of mammalian mineralized tissue. Microsc Microanal (2010) 1.45
Congenic mice provide in vivo evidence for a genetic locus that modulates intrinsic transforming growth factor β1-mediated signaling and bone acquisition. J Bone Miner Res (2012) 1.41
Fracture healing: mechanisms and interventions. Nat Rev Rheumatol (2014) 1.33
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci (2009) 1.31
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
Update on estrogens and the skeleton. J Clin Endocrinol Metab (2010) 1.25
The impact of vitamin D status on periodontal surgery outcomes. J Dent Res (2011) 1.18
Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci (2012) 1.12
Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol Cell Biol (2009) 1.12
Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int (2012) 1.08
Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLoS One (2014) 1.07
Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol (2009) 1.04
Secreted frizzled related protein 1 is a target to improve fracture healing. J Cell Physiol (2009) 1.01
Novel oxysterols have pro-osteogenic and anti-adipogenic effects in vitro and induce spinal fusion in vivo. J Cell Biochem (2011) 0.99
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone (2011) 0.98
Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res (2014) 0.97
Serum response factor regulates bone formation via IGF-1 and Runx2 signals. J Bone Miner Res (2012) 0.95
Runx2 and bone morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during osteoblast maturation. J Cell Physiol (2009) 0.95
Premature osteoblast clustering by enamel matrix proteins induces osteoblast differentiation through up-regulation of connexin 43 and N-cadherin. PLoS One (2011) 0.95
Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem (2013) 0.94
Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation. J Bone Miner Res (2011) 0.93
Sclerostin deficient mice rapidly heal bone defects by activating β-catenin and increasing intramembranous ossification. Biochem Biophys Res Commun (2013) 0.93
Lef1DeltaN binds beta-catenin and increases osteoblast activity and trabecular bone mass. J Biol Chem (2011) 0.92
Sesamin stimulates osteoblast differentiation through p38 and ERK1/2 MAPK signaling pathways. BMC Complement Altern Med (2012) 0.91
Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL-37 treated monocytes. PLoS One (2010) 0.89
Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development. Mol Cell Biol (2011) 0.89
Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle (2015) 0.88
Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacol Sin (2009) 0.88
Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res (2013) 0.87
Porous CaP/silk composite scaffolds to repair femur defects in an osteoporotic model. J Mater Sci Mater Med (2013) 0.86
Runx2 trans-activation mediated by the MSX2-interacting nuclear target requires homeodomain interacting protein kinase-3. Mol Endocrinol (2010) 0.86
The orphan nuclear receptor SHP is a positive regulator of osteoblastic bone formation. J Bone Miner Res (2010) 0.86
Strategies of spinal fusion on osteoporotic spine. J Korean Neurosurg Soc (2011) 0.86
Determinants of bone strength and quality in diabetes mellitus in humans. Bone (2015) 0.85
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Bone morphogenetic protein-7 accelerates fracture healing in osteoporotic rats. Indian J Orthop (2013) 0.85
Treatment with N- and C-terminal peptides of parathyroid hormone-related protein partly compensate the skeletal abnormalities in IGF-I deficient mice. PLoS One (2014) 0.83
Single bout short duration fluid shear stress induces osteogenic differentiation of MC3T3-E1 cells via integrin β1 and BMP2 signaling cross-talk. PLoS One (2013) 0.83
The biomaterial-mediated healing of critical size bone defects in the ovariectomized rat. Osteoporos Int (2014) 0.82
Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. PLoS One (2012) 0.82
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. PLoS One (2015) 0.81
Physiological systems under pressure. J Clin Invest (2008) 0.81
Role of bone morphogenetic protein-2 in osteogenic differentiation of mesenchymal stem cells. Mol Med Rep (2015) 0.81
Osteoporotic fracture and parathyroid hormone. World J Orthop (2011) 0.81
IGF1 potentiates BMP9-induced osteogenic differentiation in mesenchymal stem cells through the enhancement of BMP/Smad signaling. BMB Rep (2016) 0.80
Repression of osteoblast maturation by ERRα accounts for bone loss induced by estrogen deficiency. PLoS One (2013) 0.80
Bone sparing effect of a novel phytoestrogen diarylheptanoid from Curcuma comosa Roxb. in ovariectomized rats. PLoS One (2013) 0.80
The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model. Acta Pharmacol Sin (2014) 0.80
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev (2016) 0.79
The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro. Int J Endocrinol (2014) 0.79
IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med (2013) 0.79
Influence of alendronate and endplate degeneration to single level posterior lumbar spinal interbody fusion. Korean J Spine (2014) 0.79
Building bones by knocking down genes. Nat Med (2012) 0.79
Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging (2012) 0.79
Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev (2015) 0.78
Wnt signaling in bone. Clin Pediatr Endocrinol (2010) 0.78
Nmp4/CIZ closes the parathyroid hormone anabolic window. Crit Rev Eukaryot Gene Expr (2012) 0.77
Characterization of skeletal alterations in a model of prematurely aging mice. Age (Dordr) (2012) 0.77
A novel function for lysyl oxidase in pluripotent mesenchymal cell proliferation and relevance to inflammation-associated osteopenia. PLoS One (2014) 0.77
Danshen enhanced the estrogenic effects of Qing E formula in ovariectomized rats. BMC Complement Altern Med (2016) 0.77
Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation. BMC Musculoskelet Disord (2013) 0.76
Aryl hydrocarbon receptors in osteoclast lineage cells are a negative regulator of bone mass. PLoS One (2015) 0.76
Ginsenoside Rg1 promotes osteogenic differentiation of rBMSCs and healing of rat tibial fractures through regulation of GR-dependent BMP-2/SMAD signaling. Sci Rep (2016) 0.76
Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations. PLoS One (2011) 0.76
Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model. Arthritis Res Ther (2016) 0.75
Implant Composed of Demineralized Bone and Mesenchymal Stem Cells Genetically Modified with AdBMP2/AdBMP7 for the Regeneration of Bone Fractures in Ovis aries. Stem Cells Int (2016) 0.75
The effect of locally delivered recombinant human bone morphogenetic protein-2 with hydroxyapatite/tri-calcium phosphate on the biomechanical properties of bone in diabetes-related osteoporosis. J Orthop Traumatol (2014) 0.75
COMP-angiopoietin1 potentiates the effects of bone morphogenic protein-2 on ischemic necrosis of the femoral head in rats. PLoS One (2014) 0.75
Pathogenesis of Osteoporosis. Transl Endocrinol Metab (2010) 0.75
Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice. Br J Nutr (2015) 0.75
A paradigm for the development and evaluation of novel implant topologies for bone fixation: in vivo evaluation. J Biomech (2012) 0.75
Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses. Lasers Med Sci (2016) 0.75
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocr Rev (2017) 0.75
Bone diseases: Romosozumab - on track or derailed? Nat Rev Endocrinol (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 13.53
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell (2005) 8.16
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development (2006) 7.08
Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell (2005) 6.90
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science (1991) 5.71
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 4.47
Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell (2001) 4.36
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab (2006) 4.33
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development (2004) 3.89
The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest (2007) 3.76
Wnt signaling in osteoblasts and bone diseases. Gene (2004) 3.72
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest (1999) 3.60
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology (2007) 3.46
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res (2006) 3.44
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev (2005) 3.38
Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord (2006) 3.25
Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem (2006) 3.10
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol (2004) 3.09
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89
Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med (2005) 2.72
Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem (2004) 2.71
Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem (2007) 2.69
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A (2005) 2.67
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res (2006) 2.61
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol (2002) 2.55
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology (1995) 2.44
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology (1982) 2.21
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med (2007) 2.14
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem (2005) 2.04
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM : V. A STUDY OF THE BONE TRABECULAE AS A READILY AVAILABLE RESERVE SUPPLY OF CALCIUM. J Exp Med (1929) 1.85
Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res (2007) 1.82
Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res (1998) 1.82
Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem (2007) 1.79
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res (2007) 1.76
Vascular biology and the skeleton. J Bone Miner Res (2005) 1.75
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res (2002) 1.73
Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res (1999) 1.73
Upstream and downstream targets of RUNX proteins. J Cell Biochem (2003) 1.71
Bone mass is inversely proportional to Dkk1 levels in mice. Bone (2007) 1.71
Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem (2005) 1.69
TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res (2005) 1.68
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet (2005) 1.63
Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J (2006) 1.63
Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (1990) 1.55
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem (2005) 1.54
Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem (2003) 1.53
Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology (2005) 1.44
Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res (2006) 1.43
The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res (2002) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
The mechanism of coupling: a role for the vasculature. Bone (2000) 1.33
Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res (2004) 1.25
Osteocytes as multifunctional cells. J Musculoskelet Neuronal Interact (2006) 1.25
Nonunion: general principles and experimental data. Clin Orthop Relat Res (2004) 1.24
PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res (2005) 1.18
Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem (2004) 1.17
Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J Bone Miner Res (1999) 1.16
Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact (2006) 1.16
Human endothelial cells inhibit BMSC differentiation into mature osteoblasts in vitro by interfering with osterix expression. J Cell Biochem (2006) 1.15
Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem (2005) 1.15
Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem (2004) 1.12
A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res (2003) 1.07
Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol (2007) 1.06
Reduced relative risk of fractures among users of lithium. Calcif Tissue Int (2005) 1.05
Lithium use and the risk of fractures. Bone (2006) 0.99
Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron (2005) 0.98
The molecular basis of osteoclast differentiation and activation. Novartis Found Symp (2001) 0.98
Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res (2000) 0.98
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Update on Wnt signaling in bone cell biology and bone disease. Gene (2011) 2.03
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today (2005) 1.84
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res (2008) 1.69
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem (2003) 1.57
TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol (2005) 1.56
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem (2003) 1.53
Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res (2005) 1.51
Estrogen and the skeleton. Trends Endocrinol Metab (2012) 1.46
Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res (2008) 1.42
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol (2004) 1.28
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Regulation of gene expression in osteoblasts. Biofactors (2010) 1.23
MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr Osteoporos Rep (2013) 1.19
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Histone deacetylases in skeletal development and bone mass maintenance. Gene (2010) 1.16
p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation. J Cell Biochem (2008) 1.16
The formin-homology-domain-containing protein FHOD1 enhances cell migration. J Cell Sci (2003) 1.13
Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem (2001) 1.13
Lymphocyte enhancer-binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts. J Cell Biochem (2006) 1.11
Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem (2013) 1.07
Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem (2008) 1.05
Histone deacetylase co-repressor complex control of Runx2 and bone formation. Crit Rev Eukaryot Gene Expr (2007) 1.05
Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells (2010) 1.05
HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression. J Biol Chem (2010) 1.05
Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res (2010) 1.04
High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem (2014) 1.03
Collagen 11a1 is indirectly activated by lymphocyte enhancer-binding factor 1 (Lef1) and negatively regulates osteoblast maturation. Matrix Biol (2008) 1.02
Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone (2012) 1.01
Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival. J Cell Biochem (2008) 1.01
Hdac-mediated control of endochondral and intramembranous ossification. Crit Rev Eukaryot Gene Expr (2011) 1.00
Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol (2008) 1.00
Wnt signaling during fracture repair. Curr Osteoporos Rep (2009) 0.98
Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A (2005) 0.96
Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J Biol Chem (2013) 0.96
Wnt10b activates the Wnt, notch, and NFκB pathways in U2OS osteosarcoma cells. J Cell Biochem (2011) 0.96
TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One (2011) 0.95
Regulation of bone turnover by sex steroids in men. J Bone Miner Res (2008) 0.95
Runx2 and bone morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during osteoblast maturation. J Cell Physiol (2009) 0.95
Osteoclast culture and resorption assays. Methods Mol Biol (2008) 0.94
Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev (2006) 0.94
Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice. J Biol Chem (2013) 0.94
Sclerostin deficient mice rapidly heal bone defects by activating β-catenin and increasing intramembranous ossification. Biochem Biophys Res Commun (2013) 0.93
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther (2010) 0.93
2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res (2007) 0.92
Lef1DeltaN binds beta-catenin and increases osteoblast activity and trabecular bone mass. J Biol Chem (2011) 0.92
Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. J Mol Histol (2007) 0.92
Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. J Biol Chem (2013) 0.91
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics (2007) 0.91
The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem (2010) 0.91
Deletion of membrane-bound steel factor results in osteopenia in mice. J Bone Miner Res (2004) 0.90
TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction. Endocrinology (2011) 0.90
TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. Endocrinology (2013) 0.89
Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. J Orthop Res (2011) 0.89
TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PLoS One (2011) 0.88
IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res (2004) 0.88
Loss of ERE binding activity by estrogen receptor-alpha alters basal and estrogen-stimulated bone-related gene expression by osteoblastic cells. J Cell Biochem (2008) 0.87
TEThered to Runx: novel binding partners for runx factors. Blood Cells Mol Dis (2010) 0.86
Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology (2010) 0.86
Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells. J Cell Physiol (2015) 0.86
Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors. J Cell Biochem (2009) 0.84
The spatiotemporal expression of TGF-beta1 and its receptors during periosteal chondrogenesis in vitro. J Orthop Res (2002) 0.83
Src regulates the activity of the mammalian formin protein FHOD1. Biochem Biophys Res Commun (2005) 0.83
Osteoblasts protect AML cells from SDF-1-induced apoptosis. J Cell Biochem (2014) 0.82
Biological strategies for improved osseointegration and osteoinduction of porous metal orthopedic implants. Tissue Eng Part B Rev (2014) 0.82
Parathyroid hormone regulates histone deacetylases in osteoblasts. Ann N Y Acad Sci (2007) 0.79
Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. Curr Osteoporos Rep (2014) 0.79
Tumor promoter-induced MMP-13 gene expression in a model of initiated epidermis. Biochem Biophys Res Commun (2004) 0.78
Influence of bone morphogenetic protein-2 on the extracellular matrix, material properties, and gene expression of long-term articular chondrocyte cultures: loss of chondrocyte stability. Tissue Eng Part A (2009) 0.78
Temporal expression patterns of BMP receptors and collagen II (B) during periosteal chondrogenesis. J Orthop Res (2002) 0.78
The mammalian formin FHOD1 interacts with the ERK MAP kinase pathway. Biochem Biophys Res Commun (2005) 0.78
Effect of decorin and dermatan sulfate on the mechanical properties of a neocartilage. Connect Tissue Res (2010) 0.78
Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations. PLoS One (2011) 0.76
Reply to vorinostat induced bone loss in mice. Bone (2013) 0.75
RUNX3 facilitates growth of Ewing sarcoma cells. J Cell Physiol (2014) 0.75
Corrigendum: Targeting cellular senescence prevents age-related bone loss in mice. Nat Med (2017) 0.75
Osteoporosis. Methods Mol Biol (2008) 0.75
Osteoporosis and osteoarthritis. Preface. Methods Mol Biol (2015) 0.75